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The p53 and NF-kB families of transcription factors 
play key roles in the regulation of cell death and cell 
viability.  Best understood are the functions of p53 - and 
its related family member p73 - in driving cell death, 
and the ability of NF-kB to promote cell survival [1-3]. 
However, more recent reports have illustrated a deeper 
complexity to this paradigm and it is clear that under 
some circumstances p53 can promote cell survival, 
while NF-kB can participate in the activation of cell 
death [3-6]. A report by Martin et al. in this issue of 
Aging provides a further link in these pathways by 
showing that NF-kB has a critical pro-apoptotic role in 
p73-dependent death following DNA damage. 
 
In their study, Martin et al. show that DNA damage-
induced apoptosis in immortalised and transformed 
mouse embryo fibroblasts depends on the presence of the 
NF-kB sub-unit, p65. Cell devoid of p65 failed to die 
following treatment with etoposide, or exposure to 
ultraviolet light (UV), although sensitivity to apoptosis 
was regained in these cells following transduction of a 
retrovirus expressing p65. Previous studies had shown a 
similar dependence on p65 for the induction of p53-
induced death in several systems [7]. However, in this 
case the cells used by Martin et al. expressed an inactive 
mutant form of p53 - so these studies reveal a further role 
for p65 in the activation of p53-independent apoptosis.  
 
The authors sought to determine at what stage NF-kB 
was essential for cell death induction. They first analyzed                                                  
Since p65 is a transactivating member of the NF-kB 
family, it was reasoned by the authors that there should 
be genes whose expression is impaired due to loss of 
p65, and that these may include genes required for cell 
death induction in these cells.  Microarray analysis 
comparing p65-null with p65-reconstituted MEFs 
revealed that the mRNA for Noxa, a BH3-only pro-
apoptotic member of the Bcl-2 family, was considerably 
reduced in p65-null cells.  Interestingly, Noxa has 
previously been shown to be a target gene of p53 and a 
critical component of p53-mediated cell death in certain 
cellular contexts [8]. Moreover, since the release of 
cytochrome  c from mitochondria is known to be 
regulated by members of the Bcl-2 family [9], Martin et 
al. decided to investigate this change in Noxa 
expression further.  Other members of the BH3 protein 











































for defects in the core apoptotic machinery, including 
analysis of expression of Apaf-1 and caspases 2, 3 and                   
9, but no differences were found.  In addition, analysis 
of the ability of cytochrome c to induce caspase 
activation in a cell free system derived from extracts of 
these p65-null cells indicated that the core apoptotic 
machinery was indeed functional in these cells.  In 
whole cells, however, it was clear that the loss of p65 
resulted in a marked impairment in the ability to release 
cytochrome  c from mitochondria following genotoxic 
stress, indicating that a defect was present in the p65-
null cells upstream of this process.   
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Noxa.  Induction of Noxa expression is known to occur 
following genotoxic stress [8, 10, 11], but the authors 
observed that this induction is also absent in p65-null 
cells.  But is this failure to induce Noxa important?  It 
would seem so, since the authors were able to show that 
expression of Noxa in the p65-null cells restored 
apoptotic sensitivity.   
 
Noxa belongs to a group of genes that are 
transcriptionally activated by members of the p53 
family, including p73, which are themselves activated 
in response to DNA damage. Since their cells did not 
contain functional p53, Martin et al. considered whether 
p73 might be playing a role in the regulation of Noxa 
expression. While the cells lacking p65 showed a rather 
weak activation of p73β expression in response to 
etoposide, both background and stress induced 
expression of p73β was greatly enhanced in p65-
reconstituted cells. The importance of p73β in driving 
Noxa expression was established using a naturally 
occurring dominant-negative form of p73 (DN-p73β). 
Interestingly, although the induction of Noxa in the 
p65-reconstituted cells was completely ablated by DN-
p73β, the ectopic expression of a transactivation-
competent version of p73β failed to activate expression 
of Noxa in the p65-null cells. So taken together it would 
seem that both p65 and p73 are required for Noxa 
induction – both are necessary but neither is sufficient.  
 
These findings not only provide another context in 
which NF-kB has a pro-apoptotic role, but also 
highlight an interesting interplay between NF-kB and 
p73.  Clearly, however, a number of questions still 
remain to be addressed.  Most notably, what is the 
nature of the role of p65 in the induction of Noxa? 
While the levels of p73β are clearly lower in the 
absence of p65, the failure of overexpressed p73β to 
drive Noxa expression in these cells suggests that p65 is 
doing something beyond simply regulating p73β levels. 
One obvious possibility is that p65 contributes directly 
to the transcriptional activation of Noxa, and it would 
be of interest to determine whether the Noxa promoter 
contains an NF-kB binding site.  Alternatively, does p65 
control the expression of another transcription factor 
responsible for Noxa expression, or is the effect of p65 
on Noxa completely independent of the Noxa promoter 
- for instance, through microRNA control?  In this 
regard, it would be interesting to know the 
phosphorylation status of p65 in these cells following 
DNA damage, since this has been shown to determine 
whether p65  functions as a  transcriptional  activator  or  
 
 
repressor [12].  The potential role of other NF-kB 
family members also remains to be determined - 
including p50, the usual binding partner for p65, and the 
p52/RelB components of the non-canonical NF-kB 
pathway that has recently been shown to play a role in 
pro-apoptotic NF-kB signaling [13, 14]. It might 
therefore be informative to determine the influence of 
p50 and p52/RelB on the activation of Noxa expression. 
 
Although the study from Martin et al. focuses on the 
interaction of NF-kB with p73, it is tempting to 
speculate that aberrant Noxa regulation may also 
underlie the pro-apoptotic role of NF-kB in other 
settings.  An obvious question is whether NF-kB is 
required for the activation of Noxa by p53. Could this 
explain the defect in p53-mediated apoptosis seen 
following loss of p65 in some contexts? Since p73 and 
p53 are likely to operate through the same transcript-
tional control element, any cooperation between NF-kB 
and p73 is likely to extend to p53 as well. Although such 
a mechanism is an attractive model to explain some 
aspects of the interaction between p53 and NF-kB, this 
relationship is clearly much more complicated. Indeed, 
several studies have documented the ability of NF-kB to 
inhibit p53-mediated apoptosis, for example through an 
NF-kB-mediated decrease of p53 stability [15]. We still 
seem to be a long way from fully understanding the 
intricate dance between NF-kB and p53. 
 
Finally, it is worth considering the implications of these 
findings on the development and treatment of human 
cancer.  Transactivating (TA)-p73 has recently been 
shown to be a tumour suppressor in its own right, and 
chemotherapeutic responses have been thought for some 
time to be mediated, at least in part, through induction 
of p73 [16, 17]. NF-kB, on the other hand, is generally 
considered to play a tumor-promoting role, through its 
anti-apoptotic activity, and simultaneous activation of 
p53 and inhibition of NF-kB is likely to be a highly 
desirable goal for cancer therapeutics in many situations 
[18]. The pursuit of NF-kB inhibitors for cancer therapy 
will be tempered, however, by the paradoxical 
observations that inhibition of NF-kB can also 
contribute to tumor development in xenografts and 
mouse models of skin cancer, and that expression of β-
catenin and HSCO has been shown to promote 
oncogenesis - at least in part - by inhibiting NF-kB [5, 
6, 19-21]. We obviously need to understand this Jekyll 
and Hyde behavior of NF-kB to make the best use of 
any drugs based on inhibiting its activity. To this end, 
the findings presented by Martin et al. provide an 
interesting mechanistic basis to explain at least some of 
the pro-apoptotic functions of NF-kB. 
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